Work

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

Year: 2022

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(22)01023-1

Authors: K. Reckamp, Z. Song, S. Gettinger, E.P. Mitchell, J.J. Wright, J.A. Moscow, R.J. Gray, V. Wang, L.M. McShane, L.V. Rubinstein, D.R. Patton, P.M. Williams, S.R. Hamilton, B.A. Conley, C.L. Arteaga, L.N. Harris, P.J. O’Dwyer, A.P. Chen, K.T. Flaherty

Institutions: Cedars-Sinai Medical Center, Dana-Farber Cancer Institute, Yale University, Thomas Jefferson University Hospital, National Institutes of Health, National Cancer Institute, Frederick National Laboratory for Cancer Research, City Of Hope National Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Pennsylvania, Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Susan G. Komen, National Institutes of Health, National Cancer Institute

Awards: ECOG-ACRIN Network Group Operations Center, Yale Cancer Center NCTN LAPS, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, G9000029566, G9000114737, G9000327439

OpenAlex ID: W4307907154

FWCI: 0.141

Cites:

Cited by: 1

Related to: 10